From the first partial epigenetic reprogramming IND cleared by the FDA to the PEARL rapamycin trial with human healthspan data, 2025–2026 marks the moment longevity science started producing human evidence.
For two decades, the longevity field produced extraordinary results in mice — and then watched those results fail to translate, or simply never get tested in humans. That era is ending. In the past twelve to eighteen months, a cluster of breakthroughs have moved from preclinical models toward human trials or produced landmark mechanistic data that sets the stage for first-in-human studies. Some represent genuine human firsts. Some are compelling mouse results pointing directly at imminent human trials. All of them matter. Here is what happened, what the evidence actually shows, and what you can do about it today.
On January 28, 2026, Life Biosciences — the company co-founded by David Sinclair — announced FDA clearance of its Investigational New Drug (IND) application for ER-100, the first partial epigenetic reprogramming gene therapy to receive FDA permission to enter human trials.
ER-100 is being tested in Phase 1 for two age-related optic neuropathies: non-arteritic anterior ischemic optic neuropathy (NAION) and open-angle glaucoma. These diseases were chosen as a proof-of-concept because retinal ganglion cells are accessible, their degeneration is measurable, and they are among the earliest tissues to show age-related decline. Phase 1 dosing was initiated in Q1 2026.
The broader significance is in the platform, not the specific indication. ER-100 uses a modified version of the Yamanaka reprogramming factors to partially reset the epigenetic state of aging cells without converting them to a pluripotent state. Sinclair's 2023 Cell paper established the theoretical basis. The IND clearance means the FDA has reviewed the preclinical data package — including extensive nonhuman primate safety studies — and judged the risk acceptable for human testing. The eye is the starting point; the platform, if it demonstrates safety, is applicable far more broadly.
What you can do now: NAD+ precursors support the sirtuin enzymes that are central to Sinclair's epigenetic aging model. They do not reprogram cells, but they maintain the same biochemical pathways.
Recommended reading — the full scientific case for the epigenetic information theory of aging:
In March 2026, Azalea Therapeutics — a spinout from Jennifer Doudna's lab at the Innovative Genomics Institute — published a landmark paper in Nature demonstrating that CAR-T cells can be engineered directly inside a living organism. The approach uses site-specific genomic integration to reprogram T cells in vivo, without extracting and modifying them in a laboratory.
The results were in mice: the in vivo CAR-T approach successfully cleared tumors in mouse cancer models. No human has been dosed yet. First-in-human trials are expected but have not started as of early 2026.
The significance is in what this makes possible. Standard CAR-T therapy requires removing a patient's T cells, engineering them ex vivo over several weeks, and reinfusing them — a process that costs hundreds of thousands of dollars and cannot scale globally. An in vivo approach delivered by a single injection would fundamentally change the economics and logistics of cell therapy. For the longevity field, the future implication is the potential for targeted clearance of senescent cells or other aging-related cellular populations without systemic drug delivery. That application remains years away, but the platform proof is now published.
In 2025, a baby named KJ Muldoon was diagnosed with CPS1 deficiency, a severe genetic metabolic disorder that would have been fatal without liver transplantation. The team at Children's Hospital of Philadelphia and Penn Medicine designed, manufactured, and delivered a custom CRISPR base edit — correcting KJ's specific mutation in liver cells in vivo. Seven months elapsed from diagnosis to functional therapeutic intervention.
This is confirmed as the first personalized in-body CRISPR edit. Every prior therapeutic CRISPR application had used standardized edits targeting known mutations in large patient populations. KJ's treatment was designed for a single patient's unique genetic sequence. The speed — seven months from a novel diagnosis to a working bespoke molecular therapy — is the headline. It demonstrates that the regulatory and manufacturing infrastructure for personalized genomic medicine can now move faster than most observers expected. That infrastructure, built for rare pediatric diseases, becomes the blueprint for broader applications.
Kyverna Therapeutics' mivocabtagene autoleucel (miv-cel, formerly KYV-101) — an anti-CD19 CAR-T cell therapy — has generated compelling remission data across multiple autoimmune diseases and is now advancing toward what would be the first FDA approval of a CAR-T therapy for an autoimmune indication.
The pivotal registrational data comes from the KYSA-8 trial in stiff person syndrome (SPS), a severe neurological autoimmune disease where the primary endpoint was achieved. In earlier-phase trials across lupus (SLE), systemic sclerosis, and other B-cell-driven autoimmune conditions, patients have achieved drug-free remission — some with sustained remission lasting months to years off all immunosuppressive therapy.
The mechanism: CD19-targeting CAR-T therapy depletes the B-cells driving pathological immune attacks. When the immune system reconstitutes from hematopoietic stem cells, it does so without the autoreactive memory that caused the original disease. Chronic autoimmune conditions are major drivers of inflammation-driven biological aging; effective reset therapy for these conditions has meaningful longevity implications beyond treating the disease itself.
A patient received a kidney from an eGenesis pig edited at 69 genetic loci and remained off dialysis for 271 days — establishing a new benchmark for xenotransplantation in humans. The 69 edits include inactivation of endogenous retroviruses integrated in the pig genome (59 genes), plus edits to remove pig-specific antigens and introduce human immune tolerance genes.
The FDA has cleared eGenesis to proceed with a formal clinical trial. Organ failure — particularly kidney failure — is one of the most common mechanisms by which aging directly causes death. The kidney donor shortage means that the majority of patients on dialysis will die waiting. A scalable xenotransplantation solution removes one of the most predictable end-stage failure modes of the aging body.
Retro Biosciences, the longevity company backed by Sam Altman with a stated mission of adding ten healthy years to human lifespan, has dosed the first participant in a clinical trial of RTR242 — a small-molecule drug designed to restore lysosomal function and boost autophagic flux. RTR242 is being tested in Phase 1 for Alzheimer's disease.
The therapeutic rationale connects directly to aging biology: lysosomal dysfunction is one of the primary mechanisms by which aging cells accumulate damaged proteins and dysfunctional organelles. When lysosomes fail, the cellular waste-handling system backs up, contributing to neurodegeneration and accelerated aging. RTR242 targets the pathway where this failure originates. Phase 1 is a safety study; efficacy readouts will follow in later phases.
This is the most immediately actionable item on this list because GLP-1 agonists are widely available and now carry a substantially stronger evidence base for effects beyond metabolic disease.
The SELECT trial — a 17,604-patient randomized controlled trial of semaglutide versus placebo in adults with cardiovascular disease but without diabetes — reported statistically significant reductions in all-cause mortality, cardiovascular death, and major cardiovascular events. The heart failure, kidney, and cognitive datasets from SELECT and subsequent analyses have shown effects that exceed what weight loss alone would explain, pointing toward direct anti-inflammatory and organ-protective mechanisms.
These are not effects expected from a weight-loss drug. GLP-1 receptor activation appears to engage aging-relevant mechanisms at a systemic level — including inflammatory pathway modulation and direct organ protection. Whether this constitutes a true "longevity" effect on lifespan (rather than healthspan) remains to be formally tested, but the mortality reduction data from SELECT is among the strongest human trial results in metabolic medicine in the past decade.
For those who cannot or choose not to use prescription GLP-1 agonists, berberine is the most studied accessible compound with partial mechanistic overlap: it activates AMPK, improves insulin sensitivity, and modulates glucose metabolism.
Recommended reading — the most rigorous practitioner framework for understanding metabolic health and longevity:
Insilico Medicine's ISM001-055 (rentosertib) — a drug designed entirely by generative AI to target TNIK (Traf2- and NCK-interacting kinase) — reported positive Phase IIa efficacy results for idiopathic pulmonary fibrosis (IPF). This is the first AI-generated drug molecule to demonstrate efficacy in humans in a controlled trial.
Fibrosis is a primary mechanism of age-related organ failure — lungs, kidneys, and livers progressively accumulate scar tissue as part of biological aging. An effective anti-fibrotic targeting the underlying mechanism rather than downstream symptoms would have implications far beyond IPF. The AI design process identified TNIK as a novel target that had not previously been pursued for fibrosis, demonstrating that generative AI can find therapeutic targets human researchers might not have selected.
Compass Pathways has completed two pivotal Phase 3 trials of COMP360 psilocybin for treatment-resistant depression (TRD), with both achieving their primary endpoints — the first in June 2025 and the second in February 2026. This is the largest clinical trial program in the history of psychedelic medicine.
The longevity connection is specific but real: chronic treatment-resistant depression is associated with accelerated biological aging, elevated inflammatory markers, telomere shortening, and substantially increased all-cause mortality risk. Effective treatment for a condition that has resisted all prior interventions removes one of the most consistent biological aging accelerants in the affected population.
Psilocybin's mechanism involves acute disruption of the default mode network followed by a period of heightened neuroplasticity during which therapeutic processing occurs. Two separate large Phase 3 trials achieving primary endpoints establishes a very high level of clinical evidence for this mechanism.
The most directly significant result for the longevity field is the PEARL trial — the first dedicated prospective human healthspan trial of rapamycin in healthy older adults, designed to test whether the field's most robustly validated animal longevity drug produces measurable benefits in humans (PMID: 40188830, published April 2025 in Aging (Albany NY), DOI: 10.18632/aging.206235).
PEARL was a 48-week, double-blind, randomized, placebo-controlled trial in 114 healthy adults aged 50–85 who were interested in off-label rapamycin use. Participants were randomized to 10 mg weekly, an intermediate dose, or placebo. The trial reported measurable improvements in multiple healthspan biomarkers in the treated groups compared to placebo.
This matters because rapamycin's animal data is the strongest in the entire longevity pharmacology field — it is the only compound to have extended lifespan in every organism tested, and in the NIA Interventions Testing Program it extended both median and maximum lifespan in both sexes. PEARL is the first prospective evidence that the biological changes rapamycin produces in humans are in the direction predicted by fifteen years of animal data.
PEARL does not prove that rapamycin extends human lifespan — that would require decades of follow-up. But it is prospective, randomized, placebo-controlled, and published in a peer-reviewed journal. For physicians prescribing rapamycin off-label and patients taking it, PEARL is the first trial result they can point to.
Rapamycin inhibits mTOR, a master regulator of cellular growth that when chronically active drives the accumulation of damaged proteins, senescent cells, and dysfunctional mitochondria. Weekly pulsed dosing — the protocol used in PEARL and in most longevity prescribing — intermittently suppresses mTORC1 while allowing mTORC2 to recover.
To be precise about what the evidence actually shows:
| Breakthrough | Human data? |
| Life Biosciences epigenetic reprogramming | Phase 1 initiated Q1 2026 — safety data pending |
| Azalea in vivo CAR-T | Mouse data only (Nature, March 2026) — human trials not yet started |
| Baby KJ CRISPR | Confirmed human — single patient case |
| Kyverna autoimmune CAR-T | Confirmed human — Phase 3 SPS data; earlier-phase lupus data |
| Pig kidney xenotransplantation | Confirmed human — individual cases; formal trial now FDA-cleared |
| Retro Bio RTR242 | Phase 1 first-in-human — safety data pending |
| GLP-1 agonists mortality | Confirmed human — SELECT trial (17,604 patients, RCT) |
| Insilico AI drug | Confirmed human — Phase IIa positive efficacy |
| Compass psilocybin | Confirmed human — two Phase 3 RCTs |
| Rapamycin PEARL | Confirmed human — 48-week RCT, PMID 40188830 |
The breakthroughs in this article range from already available (GLP-1 agonists, berberine as an accessible option) to years from any clinical availability (in vivo CAR-T, epigenetic reprogramming). The practical takeaway is not to wait for these technologies — it is to build the biological foundation that will benefit most from them when they arrive.
The interventions with the strongest human evidence today remain unchanged: sleep quality, Zone 2 cardio, resistance training, metabolic health management, and senolytics. These work on the same underlying mechanisms that these breakthrough technologies are targeting — cellular senescence, mitochondrial function, inflammation, insulin signaling, and epigenetic maintenance.
Foundation supplements that support the pathways these technologies target:
*Affiliate disclosure: Stacking Years (Immutable ApS) participates in the Amazon Associates Programme. Links in this article are affiliate links — we earn a small commission on qualifying purchases at no extra cost to you.*